Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM

Eur J Clin Pharmacol. 1993;45(2):113-6. doi: 10.1007/BF00315490.


We have evaluated the effects of repaglinide, a new non-sulphonylurea oral hypoglycaemic agent that has a stimulatory effect on insulin secretion. Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily. While glibenclamide had a greater effect on fasting blood glucose (10.4 to 8.6 mmol.l-1), repaglinide significantly lowered postprandial blood glucose (13.8 to 12.2 mmol.l-1). Glycosylated haemoglobin remained unchanged in both groups, and serum fructosamine showed a tendency to fall. With both treatments total cholesterol was significantly decreased after 12 weeks, while HDL-cholesterol and triglycerides did not change. Fasting plasma insulin in the repaglinide group decreased from 80 (median value) to 67 pmol.l-1; it did not change in the glibenclamide group. Two patients in the repaglinide group did not complete the study, one for personal reasons, and one because of a rise in blood glucose. No abnormal findings attributable to repaglinide were observed in clinical and laboratory examinations, and no hypoglycaemic symptoms caused by it were observed.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Glucose / analysis
  • Carbamates / blood
  • Carbamates / pharmacology*
  • Carbamates / therapeutic use
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Female
  • Fructosamine
  • Gliclazide / therapeutic use
  • Glyburide / blood
  • Glyburide / pharmacology*
  • Glyburide / therapeutic use
  • Glycated Hemoglobin A / analysis
  • Hexosamines / blood
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Lipids / blood
  • Male
  • Middle Aged
  • Piperidines / blood
  • Piperidines / pharmacology*
  • Piperidines / therapeutic use
  • Tolbutamide / therapeutic use


  • Blood Glucose
  • Carbamates
  • Glycated Hemoglobin A
  • Hexosamines
  • Hypoglycemic Agents
  • Lipids
  • Piperidines
  • Fructosamine
  • repaglinide
  • Tolbutamide
  • Gliclazide
  • Glyburide